Abstract
Deep brain stimulation (DBS) surgery is the gold standard therapeutic intervention in Parkinson’s disease (PD) with motor complications, notwithstanding drug therapy. In the intraoperative evaluation of DBS’s efficacy, neurologists impose a passive wrist flexion movement and qualitatively describe the perceived decrease in rigidity under different stimulation parameters and electrode positions. To tackle this subjectivity, we designed a wearable device to quantitatively evaluate the wrist rigidity changes during the neurosurgery procedure, supporting physicians in decision-making when setting the stimulation parameters and reducing surgery time. This system comprises a gyroscope sensor embedded in a textile band for patient’s hand, communicating to a smartphone via Bluetooth and has been evaluated on three datasets, showing an average accuracy of 80%. In this work, we present a system that has seen four iterations since 2015, improving on accuracy, usability and reliability. We aim to review the work done so far, outlining the iHandU system evolution, as well as the main challenges, lessons learned, and future steps to improve it. We also introduce the last version (iHandU 4.0), currently used in DBS surgeries at São João Hospital in Portugal. © 2020 by the authors.

Abstract

Abstract

Abstract
Magnetic resonance imaging (MRI) is the most commonly used exam for diagnosis and follow-up of neurodegenerative diseases, such as multiple sclerosis (MS). MS is a neuroinflammatory and neurodegenerative disease characterized by demyelination of neuron axon. This demyelination process causes lesions in white matter that can be observed in vivo by MRI. Such lesions may provide quantitative assessments of the inflammatory activity of the disease. Quantitative measures based on various features of lesions have been shown to be useful in clinical trials for evaluating therapies. Although manual segmentations are considered as the gold standard, this process is time consuming and error prone. Therefore, automated lesion identification and quantification of the MRI are active areas in MS research. The purpose of this study was to perform the brain lesions volumetric quantification in MS patients, after segmentation via a convolutional neural network (CNN) model. Initially, MRI was rigidly registered, skullstripped and bias corrected. After, we use the CNN for brain lesions segmentation, which used training data to identify lesions within new test subjects. Finally, volume quantification was performed with a count of segmented voxels and represented by mm(3). We did not observe a statistical difference between the volume of brain lesion automatically identified and the volume manually segmented. The use of deep learning techniques in health is constantly developing. We observed that the use of these computational method for segmentation and quantification of brain lesions can be applied to aid in diagnosis and follow-up of MS.

Abstract

Abstract
With the advent of personalized medicine, there is a movement to develop "smaller" and "smarter" microdevices that are able to distinguish similar cancer subtypes. Tumor cells display major differences when compared to their natural counterparts, due to alterations in fundamental cellular processes such as glycosylation. Glycans are involved in tumor cell biology and they have been considered to be suitable cancer biomarkers. Thus, more selective cancer screening assays can be developed through the detection of specific altered glycans on the surface of circulating cancer cells. Currently, this is only possible through time-consuming assays. In this work, we propose the "intelligent" Lab on Fiber (iLoF) device, that has a high-resolution, and which is a fast and portable method for tumor single-cell type identification and isolation. We apply an Artificial Intelligence approach to the back-scattered signal arising from a trapped cell by a micro-lensed optical fiber. As a proof of concept, we show that iLoF is able to discriminate two human cancer cell models sharing the same genetic background but displaying a different surface glycosylation profile with an accuracy above 90% and a speed rate of 2.3 seconds. We envision the incorporation of the iLoF in an easy-to-operate microchip for cancer identification, which would allow further biological characterization of the captured circulating live cells.